Prime Medicine Q2 net loss $42.1M; IND/CTA clearances for PM577a, arbitration win for PM647

Prime Medicine, Inc.

2026-Q2 EPS reported -$0.51

Net loss of $42.1M for Q2 2026 vs $52.6M in Q2 2025; R&D expenses $33.4M.
Cash, equivalents, investments, restricted cash $108.8M as of June 30, 2026; runway into 2027.
FDA cleared IND for PM577a in Wilson disease; Medsafe cleared CTA in New Zealand; global Phase 1/2 study startup underway.
Arbitration with Beam Therapeutics resolved favorably; PM647 rights secured; IND/CTA submission expected Q3 2026.
FDA granted RMAT designation to PM359 for CGD; BLA submission planned for 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.